The estimated Net Worth of John B Rhodes is at least $3.52 Tausend dollars as of 1 June 2018. John Rhodes owns over 7,500 units of Tonix Pharmaceuticals Corp stock worth over $3,521 and over the last 12 years John sold TNXP stock worth over $0.
Sign up
John Rhodes TNXP stock SEC Form 4 insiders trading
John has made over 6 trades of the Tonix Pharmaceuticals Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently John bought 7,500 units of TNXP stock worth $24,975 on 1 June 2018.
The largest trade John's ever made was buying 25,000 units of Tonix Pharmaceuticals Corp stock on 31 October 2016 worth over $3,750. On average, John trades about 4,568 units every 53 days since 2013. As of 1 June 2018 John still owns at least 23,470 units of Tonix Pharmaceuticals Corp stock.
You can see the complete history of John Rhodes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's John Rhodes's mailing address?
John's mailing address filed with the SEC is C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVENUE, SUITE 1608, NEW YORK, NY, 10022.
Insiders trading at Tonix Pharmaceuticals Corp
Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over $155,884 worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth $3,399,062 . The most active insiders traders include Ernest Mario, Seth Lederman und Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of $2,734. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth $34,200.
What does Tonix Pharmaceuticals Corp do?
tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.
What does Tonix Pharmaceuticals Corp's logo look like?
Complete history of John Rhodes stock trades at Tonix Pharmaceuticals Corp
Tonix Pharmaceuticals Corp executives and stock owners
Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include:
-
Seth Lederman,
Chairman of the Board, President, Chief Executive Officer -
Dr. Seth Lederman M.D.,
Co-Founder, Pres, CEO & Chairman -
Dr. Seth Lederman,
Co-Founder, Pres, CEO & Chairman -
Dr. Gregory M. Sullivan M.D.,
Chief Medical Officer & Sec. -
Gregory Sullivan,
Secretary, Chief Medical Officer -
Bradley Saenger CPA, CPA,
CFO & Treasurer -
Bradley Saenger,
Chief Financial Officer, Treasurer -
Richard Bagger,
Director -
Herbert Harris,
Executive Vice President - Translational Medicine -
David Grange,
Independent Director -
Margaret Bell,
Independent Director -
James Treco,
Lead Independent Director -
Adeoye Olukotun,
Independent Director -
Daniel Goodman,
Independent Director -
Jessica Morris,
Chief Operating Officer -
Dr. Sina Bavari Ph.D.,
Exec. VP of Infectious Disease R&D -
Dr. Anthony Macaluso Ph.D.,
Exec. VP of Strategic Devel. -
Dr. Darryl Rideout Ph.D.,
Exec. VP of Experimental Chemistry -
Siobhan Fogarty B.Sc., M.Sc.,
Exec. VP of Product Devel. -
Dr. Bruce L. Daugherty M.B.A., Ph.D.,
Exec. VP of Research -
Dr. Herbert W. Harris M.D., Ph.D.,
Exec. VP of Translational Medicine -
Dr. R. Michael Gendreau,
Consultant -
Dr. Daniel J. Clauw M.D.,
Consultant -
Dr. Ronald R. Notvest,
Exec. VP of Commercial Planning and Devel. -
Jessica Edgar Morris,
Chief Operating Officer -
Charles E Iv Mather,
Director -
Ernest Mario,
Director -
John B Rhodes,
Director -
Samuel R Saks,
Director -
Patrick P Grace,
Director -
Bruce Daugherty,
See Remarks -
Stuart Davidson,
Director -
Donald J Kellerman,
See Remarks -
Leland Gershell,
CFO and Treasurer -
Carolyn E. Taylor,
Director -
Richard Newcomb Stillwell,
Director